Insulin 1556 (insulin) NDC 63083-1556

NDC codes

FDA NDC Directory

Product NDC (as listed)63083-1556Labeler and product segments. Claims need a package NDC.

Product NDC at billing width63083-1556Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
63083-1556-1	63083155601	29.5 mL in 1 BOTTLE, DROPPER (63083-1556-1)Marketed from Aug 15, 1985

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Insulin 1556Suffix: 1556
Generic name (nonproprietary): insulin
Active ingredients: Insulin glargine — 9 [hp_X]/29.5mL
Dosage form: Liquid
Route: Oral
Labeler: Professional Complementary Health Formulas
Product type: Over-the-counter drug
Marketing category: Unapproved homeopathic
Marketing start: Aug 15, 1984
Listing expires: Dec 31, 2027
Other FDA classes: Insulin (Chemical structure)
Identifiers: Product ID 63083-1556_c3c5ae59-b449-474d-8b9c-80f1e5e4eb7bSPL ID c3c5ae59-b449-474d-8b9c-80f1e5e4eb7bSPL set ID 88170080-374d-456e-90bc-48e873878ce7UNII 2ZM8CX04RZ
Pharmacologic class: Insulin Analog

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N463083155601 followed by a unit qualifier and the quantity

Package 63083-1556-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 8, 2026.

Indications (excerpt from the label)

INDICATIONS For the temporary relief of general weakness, debilitation, excessive sweating, or minor skin rash or hives due to sensitivity to phenolic compounds found in foods or other products.*

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)